Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06913075
NA

FET in Adenomyosis

Sponsor: Indira IVF Hospital Pvt Ltd

View on ClinicalTrials.gov

Summary

Purpose of the Study: To compare the effectiveness of GnRH agonist downregulation alone versus GnRH agonist combined with letrozole in improving pregnancy outcomes in women with adenomyosis undergoing frozen embryo transfer (FET). Research Question: Is the combined use of GnRH agonist and letrozole more effective than GnRH agonist downregulation alone in achieving better ongoing pregnancy rates in adenomyosis cases undergoing FET? Hypothesis: Null Hypothesis (H₀): The combined use of GnRH agonist and letrozole is not more effective than GnRH agonist downregulation alone in achieving a higher ongoing pregnancy rate in adenomyosis cases undergoing FET. Study Outcomes: Primary Outcome: Ongoing pregnancy rate at 12 weeks of gestation.

Official title: Is GnRH Agonist Plus Letrozole a Better Choice Than GnRH Agonist Alone in Adenomyosis Cases Undergoing Frozen Embryo Transfer?

Key Details

Gender

FEMALE

Age Range

21 Years - 42 Years

Study Type

INTERVENTIONAL

Enrollment

700

Start Date

2026-06-25

Completion Date

2026-12-23

Last Updated

2026-01-26

Healthy Volunteers

No

Conditions

Interventions

DRUG

GnRH agonist downregulation

Triptorelin Acetate 3.75mg for two consecutive dosage at 30 days interval

DRUG

GnRH agonist and Letrozole

Triptorelin Acetate 3.75mg for two consecutive dosages at 30 days interval) + Letrozole (5 mg once daily for a total of 21 days during the second depot - letrozole stops when Estrogen priming starts

Locations (1)

Indira IVF Pvt Hospital

Udaipur, Rajasthan, India